Dec 19, 2023 9:00am EST Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
Dec 13, 2023 9:00am EST Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
Nov 30, 2023 8:15am EST Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
Nov 29, 2023 8:15am EST Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
Nov 13, 2023 1:40pm EST Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
Nov 09, 2023 8:15am EST Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
Nov 01, 2023 8:15am EDT Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders
